Tonix Pharmaceuticals Holding Corp (LTS:0A4T)
$ 134.6 0 (0%) Market Cap: 17.80 Mil Enterprise Value: 12.04 Mil PE Ratio: 0 PB Ratio: 0.39 GF Score: 31/100

Tonix Pharmaceuticals Holding Corp at SNN Network Virtual Conference Transcript

Aug 06, 2020 / 02:00PM GMT
Unidentified Analyst

Greetings, and welcome to the Tonix Pharmaceuticals Conference. It is now my pleasure to introduce your host, Dr. Seth Lederman, CEO of Tonix pharmaceuticals. Thank you, Dr. Lederman. You may begin.

Seth Lederman
Tonix Pharmaceuticals Holding Corp - Co-Founder, CEO, and Chairman

Thank you. It's exciting to be presenting Tonix to you on this digital format. We have a big group. I'm going to answer questions at the end. So, there is a Q&A system and please use it. I try to leave five minutes at the end to answer questions.

So, Tonix is a public company on NASDAQ. So, I have to take you through our standard disclaimer on the next slide. I'll be making forward-looking statements. And our SEC documents are more complete, and we soon will have our 10-Q to update financial information about the company.

Tonix is a biopharmaceutical company. We are working on important problems. We are clinical stage. We focus on small molecules and biologics. And there are two main areas, CNS or central nervous system and immunology.

In

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot